Summit Therapeutics Inc. SMMT
Regular-session close
After hours · Nov 18, 7:58 PM ET
- YTD
- -39.97%
- 1 year
- -37.54%
- Market cap
- 8.40B
- EPS (ttm)
- -1.06
- Shares out
- 799.76M
- Forward P/E
- -9.91
- YTD return
- -39.97%
- 1-year return
- -37.54%
- 50-day average
- 16.16
- 200-day average
- 16.12
- Enterprise value
- 7.92B
- Price / book
- 14.87
- Volume
- 12.09M
- Avg volume
- 6.54M
- Open
- 10.24
- Previous close
- 10.67
- Day's range
- 10.14 – 11.39
- 52-week range
- 10.14 – 29.23
- Beta
- -1.52
- Analysts
- Buy
- Price target
- 29.06 (+176.8%)
- Earnings date
- Feb 22, 2027
5D -5.69 (-35.12%)
Key statistics
- Free cash flow
- -213.92M
- Total cash
- 629.79M
- Total debt
- 19.98M
- Return on equity
- -220.01%
- Short % of float
- 26.67%
Fundamental scorecard
5 of 25 checks passed on SMMT’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 8.26
- Target (mean)
- 29.06
- Target (high)
- 42.76
- Strong buy1
- Buy10
- Hold5
- Sell0
- Strong sell1
Next earnings
Feb 22, 2027
Expected Feb 22, 2027. Consensus EPS estimate -0.2027.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 22, 2027 | Dec 30, 2026 | -0.34 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.28174 | -0.26 | +0.02 | +7.72% |
| Jul 23, 2026 | Jun 30, 2026 | -0.27439 | -0.28 | -0.01 | -2.04% |
| Apr 30, 2026 | Mar 31, 2026 | -0.33 | -0.24 | +0.09 | +27.27% |
| Feb 23, 2026 | Dec 31, 2025 | -0.10264 | -0.29 | -0.19 | -182.54% |
| Oct 20, 2025 | Sep 30, 2025 | -0.17577 | -0.31 | -0.13 | -76.37% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Sep 29, 2026 | Citigroup | main | Buy | Buy |
| Sep 23, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Sep 9, 2026 | Jefferies | up | Hold | Buy |
| Aug 26, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 25, 2026 | Bernstein | up | Underperform | Market Perform |
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- smmttx.com
News
This Insulet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Bernstein Downgrades Summit Therapeutics to Underperform, Lowers Price Target to $8.3
Summit Therapeutics Initiates Global Phase III Clinical Trial Of Ivonescimab In Non-Small Cell Lung Cancer; Expects Global Clinical Trial Site Activations For HARMONi-10 To Begin In Q4 2026
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer
Summit Therapeutics' stock tumbles again as FDA recommends new trial for lung-cancer drug
Dow Slides 1.4% as Salesforce Leads Software Rout Before Anthropic IPO: Stock Market Today Citigroup Maintains Buy on Summit Therapeutics, Lowers Price Target to $42
Summit Stock Falls on FDA Rejection for Lung Cancer Drug
2 Cancer-Drug Developers Seeing Unusual Options Volume Barclays Maintains Equal-Weight on Summit Therapeutics, Lowers Price Target to $18
Your note
Sign in to keep a note on SMMT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANAND BHASKAR | Officer | Stock Award(Grant) | Oct 7, 2026 | 261,047 |
| DUGGAN ROBERT WILLIAM | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 15, 2026 | 0 |
| SONI MANMEET SINGH | Chief Operating Officer | Conversion of Exercise of derivative security | Nov 15, 2026 | 3,224,380 |
| XIA YU | Director | Purchase | Oct 20, 2025 | 0 |
| ZANGANEH MAHKAM | Officer, Director and Beneficial Owner | Conversion of Exercise of derivative security | Nov 15, 2026 | 610,516,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 4.10% | 32,786,348 | 344.26M | Sep 29, 2026 |
| Blackrock Inc. | 1.30% | 10,363,750 | 108.82M | Sep 29, 2026 |
| FMR, LLC | 1.02% | 8,136,745 | 85.44M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 0.90% | 7,230,441 | 75.92M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 0.84% | 6,717,642 | 70.54M | Sep 29, 2026 |
| State Street Corporation | 0.76% | 6,093,474 | 63.98M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.46% | 3,707,548 | 38.93M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 0.45% | 3,635,145 | 38.17M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.33% | 2,667,317 | 28.01M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.32% | 2,531,231 | 26.58M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.26% | 2,047,862 | 21.50M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.22% | 1,778,361 | 18.67M | Jun 29, 2026 |
